Literature DB >> 9525900

Diversity of HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins.

M BouHamdan1, Y Xue, Y Baudat, B Hu, J Sire, R J Pomerantz, L X Duan.   

Abstract

Targeting protein or RNA moieties to specific cellular compartments may enhance their desired functions and specificities. Human immunodeficiency virus type I (HIV-1) encodes proteins in addition to Gag, Pol, and Env that are packaged into virus particles. One such retroviral-incorporated protein is Vpr, which is present in all primate lentiviruses. Vpr has been implicated in different roles within the HIV-1 life cycle. In testing a new hypothesis in which viral proteins are utilized as docking sites to incorporate protein moieties into virions, we used the peptide phage display approach to search for Vpr-specific binding peptides. In the present studies, we demonstrate that most of the peptides that bind to Vpr have a common motif, WXXF. More importantly, we demonstrate that the WXXF motif of uracil DNA glycosylase is implicated in the interaction of uracil DNA glycosylase with Vpr intracellularly. Finally, a dimer of the WXXF motif was fused to the chloramphenicol acetyl transferase (CAT) gene, and it was demonstrated that the WXXF dimer-CAT fusion protein construct produces CAT activity within virions in the presence of Vpr as a docking protein. This study provides a novel potential strategy in the targeting of anti-viral agents to interfere with HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525900     DOI: 10.1074/jbc.273.14.8009

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 2.  Viral infection and human disease--insights from minimotifs.

Authors:  Krishna Kadaveru; Jay Vyas; Martin R Schiller
Journal:  Front Biosci       Date:  2008-05-01

Review 3.  The functions of the HIV1 protein Vpr and its action through the DCAF1.DDB1.Cullin4 ubiquitin ligase.

Authors:  Laurieann Casey; Xiaoyun Wen; Carlos M C de Noronha
Journal:  Cytokine       Date:  2010-03-27       Impact factor: 3.861

4.  Understanding the molecular manipulation of DCAF1 by the lentiviral accessory proteins Vpr and Vpx.

Authors:  Patrick A Cassiday; Ana Beatriz DePaula-Silva; Jeffrey Chumley; Jeffrey Ward; Edward Barker; Vicente Planelles
Journal:  Virology       Date:  2014-12-11       Impact factor: 3.616

5.  Uracil-directed ligand tethering: an efficient strategy for uracil DNA glycosylase (UNG) inhibitor development.

Authors:  Yu Lin Jiang; Daniel J Krosky; Lauren Seiple; James T Stivers
Journal:  J Am Chem Soc       Date:  2005-12-14       Impact factor: 15.419

6.  A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm).

Authors:  M A Accola; A A Bukovsky; M S Jones; H G Göttlinger
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 7.  Vpr-host interactions during HIV-1 viral life cycle.

Authors:  Richard Y Zhao; Ge Li; Michael I Bukrinsky
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-12       Impact factor: 4.147

8.  Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Authors:  Bärbel Schröfelbauer; Qin Yu; Samantha G Zeitlin; Nathaniel R Landau
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 9.  HIV-1 viral protein R (Vpr) and its interactions with host cell.

Authors:  Ge Li; Michael Bukrinsky; Richard Y Zhao
Journal:  Curr HIV Res       Date:  2009-03       Impact factor: 1.581

10.  DNA repair enzyme uracil DNA glycosylase is specifically incorporated into human immunodeficiency virus type 1 viral particles through a Vpr-independent mechanism.

Authors:  K E Willetts; F Rey; I Agostini; J M Navarro; Y Baudat; R Vigne; J Sire
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.